Betamethasone dipropionate; calcipotriene - Generic Drug Details

What are the generic drug sources for betamethasone dipropionate; calcipotriene and what is the scope of patent protection?

Betamethasone dipropionate; calcipotriene is the generic ingredient in five branded drugs marketed by Glenmark Pharms Ltd, Leo Pharma As, MC2, Chartwell Rx, Padagis Israel, Cosette, and Sun Pharma Canada, and is included in ten NDAs. There are eleven patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Betamethasone dipropionate; calcipotriene has eighty-eight patent family members in thirty-three countries.

Seven suppliers are listed for this compound.

Summary for betamethasone dipropionate; calcipotriene

International Patents:	88
US Patents:	11
Tradenames:	5
Applicants:	7
NDAs:	10
Finished Product Suppliers / Packagers:	7
Clinical Trials:	17
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for betamethasone dipropionate; calcipotriene
DailyMed Link:	betamethasone dipropionate; calcipotriene at DailyMed

Recent Clinical Trials for betamethasone dipropionate; calcipotriene

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Psoriasis Treatment Center of Central New Jersey	PHASE4
University of Alabama at Birmingham	Phase 4
Eli Lilly and Company	Phase 4

See all betamethasone dipropionate; calcipotriene clinical trials

Pharmacology for betamethasone dipropionate; calcipotriene

Drug Class	Corticosteroid Vitamin D Analog
Mechanism of Action	Corticosteroid Hormone Receptor Agonists

Anatomical Therapeutic Chemical (ATC) Classes for betamethasone dipropionate; calcipotriene

A07EA	Corticosteroids acting locally
A07E	INTESTINAL ANTIINFLAMMATORY AGENTS
A07	ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS
A	Alimentary tract and metabolism

C05AA	Corticosteroids
C05A	AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE
C05	VASOPROTECTIVES
C	Cardiovascular system

D07AC	Corticosteroids, potent (group III)
D07A	CORTICOSTEROIDS, PLAIN
D07	CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS
D	Dermatologicals

D07XC	Corticosteroids, potent, other combinations
D07X	CORTICOSTEROIDS, OTHER COMBINATIONS
D07	CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS
D	Dermatologicals

H02AB	Glucocorticoids
H02A	CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN
H02	CORTICOSTEROIDS FOR SYSTEMIC USE
H	Systemic hormonal preparations, excluding sex hormones and insulins

R01AD	Corticosteroids
R01A	DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE
R01	NASAL PREPARATIONS
R	Respiratory system

R03BA	Glucocorticoids
R03B	OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS
R03	DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
R	Respiratory system

S01BA	Corticosteroids, plain
S01B	ANTIINFLAMMATORY AGENTS
S01	OPHTHALMOLOGICALS
S	Sensory organs

S01CB	Corticosteroids/antiinfectives/mydriatics in combination
S01C	ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION
S01	OPHTHALMOLOGICALS
S	Sensory organs

S02BA	Corticosteroids
S02B	CORTICOSTEROIDS
S02	OTOLOGICALS
S	Sensory organs

S03BA	Corticosteroids
S03B	CORTICOSTEROIDS
S03	OPHTHALMOLOGICAL AND OTOLOGICAL PREPARATIONS
S	Sensory organs

Paragraph IV (Patent) Challenges for BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
ENSTILAR	Topical Foam	betamethasone dipropionate; calcipotriene	0.005%/0.064%	207589	1	2020-06-22
TACLONEX	Ointment	betamethasone dipropionate; calcipotriene	0.005%/0.064%	021852	1	2010-03-31

US Patents and Regulatory Information for betamethasone dipropionate; calcipotriene

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Leo Pharma As	ENSTILAR	betamethasone dipropionate; calcipotriene	AEROSOL, FOAM;TOPICAL	207589-001	Oct 16, 2015		RX	Yes	Yes	10,716,799		Y
Padagis Israel	CALCIPOTRIENE AND BETHAMETHASONE DIPROPIONATE	betamethasone dipropionate; calcipotriene	SUSPENSION;TOPICAL	212367-001	Sep 11, 2020		DISCN	No	No
Leo Pharma As	TACLONEX	betamethasone dipropionate; calcipotriene	OINTMENT;TOPICAL	021852-001	Jan 9, 2006	AB	RX	Yes	Yes

Expired US Patents for betamethasone dipropionate; calcipotriene

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Leo Pharma As	TACLONEX	betamethasone dipropionate; calcipotriene	OINTMENT;TOPICAL	021852-001	Jan 9, 2006	RE39706
Leo Pharma As	ENSTILAR	betamethasone dipropionate; calcipotriene	AEROSOL, FOAM;TOPICAL	207589-001	Oct 16, 2015	6,753,013
Leo Pharma As	TACLONEX	betamethasone dipropionate; calcipotriene	OINTMENT;TOPICAL	021852-001	Jan 9, 2006	5,763,426

International Patents for betamethasone dipropionate; calcipotriene

Country	Patent Number	Title	Estimated Expiration
South Korea	20160054614	비타민 Ｄ 유사체 및 코르티코스테로이드를 포함하는 약제학적 분무 조성물 (A PHARMACEUTICAL SPRAY COMPOSITION COMPRISING A VITAMIN D ANALOGUE AND A CORTICOSTEROID)
China	102939078	A pharmaceutical spray composition comprising a vitamin d analogue and a corticosteroid
Croatia	P20150154

Market Dynamics and Financial Trajectory for Betamethasone Dipropionate; Calcipotriol

Last updated: February 15, 2026

---

Market Overview

Betamethasone Dipropionate in combination with Calcipotriol addresses psoriasis and atopic dermatitis. The combination is marketed mainly under brand names like Daivobet or Dovobet and is also available as generic formulations. The drug combination has maintained a significant position within topical dermatology, with an increasing global demand driven by rising prevalence of psoriasis and psoriasis-related disorders.

---

Key Market Factors

1. Disease Prevalence and Market Drivers

• Psoriasis affects approximately 2-3% of the global population, with an estimated 125 million affected individuals worldwide[1].
• Growing awareness and improved diagnosis escalate demand for topical treatments like Betamethasone Dipropionate; Calcipotriol.
• Shift from systemic to topical therapies limits long-term side effects and increases patient compliance.

2. Regulatory Landscape

• Approved in multiple markets, including FDA (U.S.), EMA (Europe), and WHO. Regulatory approval often extends to generic versions after patent expiration.
• Patent expiry for the branded combination in several markets occurred around 2014-2017, opening routes for generic production.
• Ongoing regulatory reviews in emerging markets aim to expand access and lower prices.

3. Competitive Environment

• Key players include Leo Pharma, LEO Pharma A/S, and Sandoz (Novartis), which hold patents or market authorization for branded versions.
• Generics dominate in markets with patent expiry, reducing average selling prices.
• Innovations include new formulations with improved bioavailability or reduced side effects.

4. Market Segments

• Topical creams predominate, but foam and gel formulations are gaining traction, especially for patient ease of use.
• Prescription-based sales comprise the majority; over-the-counter (OTC) sales are limited due to corticosteroid potency.

5. Regional Market Trends

• North America holds the largest market share (~40%) due to high psoriasis prevalence and healthcare expenditure.
• Europe follows, supported by aging populations and healthcare policies favoring dermatological therapies.
• Asia-Pacific exhibits rapid growth—projected CAGR of 8-10% over 2022-2030—driven by increasing healthcare infrastructure and awareness.

---

Financial Trajectory

1. Price Trends

• Branded formulations sold at premium prices: approximately $300-$400 per month per patient in the U.S.
• Generic formulations reduce costs by 50-70%, increasing accessibility.
• Average price declines observed post-patent expiration: 20-30%.

2. Revenue Estimates

• The global market value for Betamethasone Dipropionate; Calcipotriol formulations was valued at approximately $600 million in 2022[2].
• Compound annual growth rate (CAGR) estimated at 6% from 2023-2030, driven by increased demand in emerging markets.
• Leading companies report annual revenues of $50-$100 million for branded products; generic sales surpass this figure in volume terms globally.

3. Market Shares and Sales Drivers

Company	Estimated Market Share	Notable Products	Estimated Revenue (2022)
Leo Pharma	35%	Daivobet, Dovobet	$210 million
Sandoz (Novartis)	25%	Generic formulations	$150 million
Others	40%	Multiple generics	$240 million

4. Profitability Outlook

• Branded formulations maintain higher profit margins (~30-40%) due to premium pricing.
• Generics operate with lower margins (~10-15%) but benefit from higher volume sales.
• R&D investments focus on formulation improvements and new indications to sustain growth.

---

Future Trends & Opportunities

• Expansion into biosimilar space for corticosteroid and vitamin D derivatives.
• Development of combination therapies with extended-release or targeted delivery mechanisms.
• Entry into emerging markets facilitated by local manufacturing alliances.
• Regulatory approval of new indications, such as psoriatic arthritis or atopic dermatitis, to diversify revenue streams.

---

Risks & Challenges

• Patent cliff leading to commoditization and price competition.
• Regulatory hurdles for new formulations and indications.
• Market saturation in mature regions, necessitating innovation to sustain growth.
• Competition from alternate therapies including biologics, phototherapy, and systemic immunomodulators.

---

Key Takeaways

• The Betamethasone Dipropionate; Calcipotriol market is mature in developed regions but exhibits growth in emerging markets.
• Patent expiration has shifted revenue from branded to generic formulations.
• Price sensitivity and increasing competition exert pressure on profit margins.
• Future growth hinges on formulation innovation, geographic expansion, and new indication approval.

---

FAQs

Q1: How will patent expirations impact the market?
Patent expirations lead to increased generic competition, reducing prices and pressure on margins but expanding market volume.

Q2: What regions will drive future growth?
Emerging markets such as Asia-Pacific are projected to grow rapidly due to rising healthcare infrastructure and disease awareness.

Q3: Are biologics a threat to topical therapies?
Biologics and systemic immunotherapies target severe psoriasis cases but act as complementary, not replacement, to topical treatments for mild-to-moderate disease.

Q4: What are primary barriers to market expansion?
Regulatory challenges, patent litigation, and market access issues in low- and middle-income countries.

Q5: What areas of innovation could influence future revenues?
Enhanced formulations for better efficacy or reduced side effects, combination therapies, and new dermatological indications.

---

References

[1] World Health Organization. "Psoriasis Fact Sheet," 2022.
[2] MarketWatch. "Global Dermatology Market Report," 2022.